Loading this company
Heartflow, Inc.
HTFLPrices in USD
TickerWorth ScoreD43/100
What we think
Priced above our one model’s value of $15.12.
Price
$48.29USD down −$2.62 (−5.14%)
Close of · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
One model only, on today’s numbers
$15.12
What the price needs: revenue growth of more than 25%/yr for 5 years, more than our model can justify (it assumes 16.6%).
Led by peer multiples (P/E, EV/EBITDA, P/S) · Fast grower
Delayed price used by the model $51.43Prices are delayed.
Is it a good business?
- Valuation0 out of 100
- Growth100 out of 100
- Financial health100 out of 100
- Past performance33 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$47.22 across 9 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. It operates in the Health Information Services industry (Healthcare sector), headquartered in United States. The company employs roughly 843 people.
Key stats
52-week range$20.13–$54.32
- Open
- $48.70
- Day high
- $51.75
- Day low
- $48.70
- Previous close
- $48.29
- Volume
- 499,237 · 0.27× avg
- Average volume
- 1,821,768
- Market cap
- $4,490,285,056.00
- P/E (TTM)
- —
- Earnings per share
- −$0.24
- Beta
- —
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Reported quarterly or annual results
- Reported shareholder vote results
- Reported quarterly or annual results
- Reported quarterly or annual results
- Issued a public disclosure (Reg FD)
- Reported quarterly or annual results
- Reported quarterly or annual results
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Farquhar John C.M.Open-market sale · $1,928,195.20
- Rogers CampbellOption exercise ·
Not investment advice. TickerWorth Score is a model output.